English
Regional settings| Spread | 0.12 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 4.52 |
| Open | 4.54 |
| 1-Year Change | -39.3% |
| Day's Range | 4.54 - 5.13 |
ProPhase Labs, Inc. is a medical science and technology company. The Company operates through two segments: consumer products and diagnostic services. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States. The diagnostic services segment provides COVID-19 diagnostic information services to a range of customers in the United States, including health plans, third party payers and government organizations. The Company is also engaged in development and distribution of a product line of OTC dietary supplements under the brand name of TK Supplements. The TK Supplements product line offers two men’s health products, including Legendz XL for sexual health and Triple Edge XL, an energy booster plus testosterone support.
BRIEF: For the nine months ended 30 September 2021, ProPhase Labs Inc revenues increased from $9.4M to $33.9M. Net loss before extraordinary items increased from $1.3M to $4.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administration increase from $3.3M to $14.7M (expense).
Common Stock $.0005 Par, 12/10, 50M auth., 19,353,672 issd., less 4,646,053 shs. in Treas. @ $25.2M. Insiders & Stakeholder owns 43.95%. PO 2/91, 3M shares @ $.15 by Concorde Brokerage Corporation. 1/97, 2-for-1 stock split. FY '00 '01 fins. are RES due to disc. opr. Sum Qs reflect restated EPS. FY '02 Qs are restated for disc. opr.
